v3.26.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating expenses        
Research and development $ 10,824 $ 6,528 $ 32,631 $ 15,720
General and administrative 11,902 3,649 26,355 11,578
Total operating expenses 22,726 10,177 58,986 27,298
Operating loss (22,726) (10,177) (58,986) (27,298)
Other (expense) income:        
Interest expense - royalty agreement (2,814) (1,510) (7,161) (4,079)
Fair value adjustments on derivative liabilities - royalty agreement (1,648) (82) (1,878) (275)
Fair value adjustments on derivative liabilities - contingent value right liability 0 (238) 202 (238)
Interest income, net 2,551 628 5,589 2,070
Other (expense) income, net (6) 34 (46) 819
Loss before income taxes (24,643) (11,345) (62,280) (29,001)
Income tax benefit (expense) 0 0 0 0
Net loss (24,643) (11,345) (62,280) (29,001)
Other comprehensive loss:        
Unrealized loss on investments (14) 0 (40) 0
Foreign currency translation gain (loss) (19) 215 13 101
Comprehensive loss $ (24,676) $ (11,130) $ (62,307) $ (28,900)
Net loss per share of Common Stock - basic (in dollars per share) $ (1.7) $ (1.03) $ (4.45) $ (2.63)
Net loss per share of Common Stock - diluted (in dollars per share) $ (1.7) $ (1.03) $ (4.45) $ (2.63)
Weighted-average shares used in computing net loss per share of Common Stock - basic (in shares) 14,531,595 11,064,282 13,996,326 11,043,758
Weighted-average shares used in computing net loss per share of Common Stock - diluted (in shares) 14,531,595 11,064,282 13,996,326 11,043,758